Changes in the density of imidazoline-I2 binding sites have been observed in a range of
neurologic disorders including Alzheimer's disease, Huntington's chorea, and glial tumor; …

The development of a PET radioligand selective for I2-imidazoline binding sites (I2BS)
would enable, for the first time, specific, measurable in vivo imaging of this target protein …

The imidazoline2 binding site (I2BS) is thought to be expressed in glia and implicated in the
regulation of glial fibrillary acidic protein. A PET ligand for this target would be important for …

Background We measured whole body distribution of 11 C-BU99008, a new PET biomarker
for non-invasive identification of the imidazoline 2 binding site. The purpose of this phase I …

INTRODUCTION: To explore the possible use of positron emission tomography (PET)
probes for imaging of I2-imidazoline receptors (I2Rs) in peripheral tissues, we labeled two …

The density of the Imidazoline2 binding site (I2BS) has been shown to change in psychiatric
conditions such as depression and addiction, along with neurodegenerative disorders such …

I2 imidazoline receptors (I2Rs) are associated with depression, Alzheimer's disease, and
Huntington's disease. However, in vivo imaging of I2Rs in the monkey brain has not been …

INTRODUCTION: Imidazoline receptors (IRs) have been established as distinct receptors,
and have been categorized into at least two subtypes (I1R and I2R). I2Rs are associated …

Imidazoline I2 binding sites are heterogeneous in nature and have been observed in the
brain of a number of species. Development of specific imidazoline I2 radioligands, such as …

Abstract Imidazoline‐2 binding sites (I2BS) exhibit specific expression in reactive astrocytes
of the brain and are implicated in various pathophysiological processes, including …